Critical Analysis: Abliva AB (publ) (OTCMKTS:NEVPF) and Teva Pharmaceutical Industries (NYSE:TEVA)

Abliva AB (publ) (OTCMKTS:NEVPF) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Earnings and Valuation

This table compares Abliva AB (publ) and Teva Pharmaceutical Industries’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abliva AB (publ) $20,000.00 1,080.44 -$6.54 million N/A N/A
Teva Pharmaceutical Industries $16.66 billion 0.59 -$3.99 billion $2.45 3.65

Abliva AB (publ) has higher earnings, but lower revenue than Teva Pharmaceutical Industries.

Institutional and Insider Ownership

51.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.7% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Abliva AB (publ) and Teva Pharmaceutical Industries, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abliva AB (publ) 0 0 0 0 N/A
Teva Pharmaceutical Industries 0 5 2 0 2.29

Teva Pharmaceutical Industries has a consensus price target of $11.33, suggesting a potential upside of 26.63%. Given Teva Pharmaceutical Industries’ higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Abliva AB (publ).


This table compares Abliva AB (publ) and Teva Pharmaceutical Industries’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abliva AB (publ) N/A -47.81% -43.65%
Teva Pharmaceutical Industries -23.98% 23.88% 5.28%


Teva Pharmaceutical Industries beats Abliva AB (publ) on 7 of the 11 factors compared between the two stocks.

About Abliva AB (publ)

Abliva AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. Its projects include KL1333 AND NV354. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with's FREE daily email newsletter.